Related Experiment Video
Updated: Jul 25, 2026

A Method for Evaluating the Reinforcing Properties of Ethanol in Rats without Water Deprivation, Saccharin Fading or Extended Access Training
Published on: January 29, 2017
Tea consumption modulates hepatic drug metabolizing enzymes in Wistar rats
P P Maliakal1, P F Coville, S Wanwimolruk
1School of Pharmacy, University of Otago, Dunedin, New Zealand.
Abstract:
The antioxidant, antimutagenic and anticarcinogenic activities of green tea and its polyphenols have been reported. As bioactivation of the precarcinogens and detoxification of ultimate carcinogens are mainly carried out by hepatic metabolizing enzymes, we have investigated the modulation of these enzyme activities subsequent to tea consumption in rats. Female Wistar rats were divided into eight groups (n = 5). Six groups were given aqueous solutions (2%, w/v) of six different teas (New Zealand green tea, Australian green tea, Java green tea, Dragon green tea, Gunpowder green tea or English Breakfast black tea) as the sole source of fluid. One group was given a standard green tea extract (0.5%, w/v) while the control group had free access to water. At the end of four-weeks treatment, different cytochrome P450 (CYP) isoform and phase II enzyme activities were determined by incubation of the liver microsomes or cytosols with appropriate substrates. CYP 1A2 activity was markedly increased in all the tea treatment groups (P < 0.05). CYP 1A1 activity was increased significantly in most of the groups except for the Madura, Gunpowder, and Java green tea-treatment groups. Cytosolic glutathione-S-transferase activity was significantly increased (P< 0.05) in the New Zealand, Gunpowder, and Java green tea-treatment groups. The microsomal UDP-glucuronosyl transferase activity remained unchanged or was moderately increased in most of the groups. The balance between the phase I carcinogen-activating enzymes and the phase II detoxifying enzymes could be important in determining the risk of developing chemically-induced cancer.
Insights
Green tea consumption significantly boosted hepatic cytochrome P450 (CYP) 1A2 activity in rats. This suggests tea
Area of Science:
- Pharmacology and Toxicology
- Nutritional Science
- Biochemistry
Background:
- Green tea and its polyphenols exhibit antioxidant, antimutagenic, and anticarcinogenic properties.
- Hepatic metabolizing enzymes are crucial for bioactivation of precarcinogens and detoxification of ultimate carcinogens.
- Understanding tea's modulation of these enzymes is key to assessing cancer risk.
Purpose of the Study:
- To investigate how tea consumption affects hepatic metabolizing enzyme activities in rats.
- To determine the impact of different types of green and black tea on specific enzyme isoforms.
- To explore the balance between Phase I and Phase II enzymes following tea intake.
Main Methods:
- Female Wistar rats were administered aqueous solutions of six different teas or a green tea extract for four weeks.
- Control group received water.
- Liver microsomes and cytosols were analyzed for cytochrome P450 (CYP) isoform and phase II enzyme activities.
Main Results:
- All tea treatments significantly increased CYP 1A2 activity.
- CYP 1A1 activity increased in most groups, with exceptions.
- Glutathione-S-transferase activity was significantly elevated by certain green teas.
Conclusions:
- Tea consumption, particularly green tea, can modulate hepatic enzyme activities involved in carcinogen metabolism.
- The observed increase in CYP 1A2 suggests enhanced detoxification pathways.
- The balance between carcinogen-activating and detoxifying enzymes is influenced by tea intake, potentially impacting chemically-induced cancer risk.
More Related Videos
07:31Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
Published on: January 7, 2019
08:45Modeling Alcohol Consumption in Rodents Using Two-Bottle Choice Home Cage Drinking and Microstructural Analysis
Published on: November 8, 2024
Related Concept Videos
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment